(Q39330537)

11 September 2017

title

Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells (English)

1 reference

triple-negative breast cancer

11 September 2017

main subject

1 reference

8

Chikako Shimizu

1 reference

11 September 2017

12

Yasuhiro Fujiwara

1 reference

11 September 2017

7

Kan Yonemori

1 reference

11 September 2017

13

Kenji Tamura

1 reference

11 September 2017

1

Mayu Yunokawa

1 reference

11 September 2017

9

Masashi Ando

1 reference

11 September 2017

6

Makoto Kodaira

1 reference

11 September 2017

Fumiaki Koizumi

2

1 reference

11 September 2017

Yuka Kitamura

3

1 reference

11 September 2017

Yasufumi Katanasaka

4

1 reference

11 September 2017

Naoko Okamoto

5

1 reference

11 September 2017

Kenkichi Masutomi

10

1 reference

11 September 2017

Teruhiko Yoshida

11

1 reference

11 September 2017

publication date

1 August 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

103

1 reference

11 September 2017

issue

9

1 reference

11 September 2017

page(s)

1665-1671

1 reference

Triple-negative breast cancer: clinical features and patterns of recurrence

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Biphasic metaplastic sarcomatoid carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Breast cancer subtypes and the risk of local and regional relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Basal carcinoma of the breast revisited: an old entity with new interpretations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

The epithelial-mesenchymal transition generates cells with properties of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02359.X

Oncogenic mutations of PIK3CA in human cancers

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22703543

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22703543

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22703543

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1349-7006.2012.02359.X

1 reference

11 September 2017

0 references

1 reference